公开(公告)号：US20230218596A1

公开(公告)日：2023-07-13

申请号：US17995908

申请日：2021-03-16

Applicant: MEREO BIOPHARMA 4 LIMITED ,  THE UAB RESEARCH FOUNDATION

Inventor： Jacqueline PARKIN ,  James Michael WELLS ,  Mark DRANSFIELD

IPC: A61K31/444 ,  A61P31/14 ,  A61K45/06

CPC classification number: A61K31/444 ,  A61P31/14 ,  A61K45/06

Abstract: The invention relates to treatments for coronavirus infections by administering a neutrophil elastase inhibitor, such as alvelestat.

公开(公告)号：US20230159542A1

公开(公告)日：2023-05-25

申请号：US17996886

申请日：2021-04-21

Applicant: THE UAB RESEARCH FOUNDATION ,  SOUTHERN RESEARCH INSTITUTE ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： Louis B. Nabors ,  Natalia Filippova ,  Xiuhua Yang ,  Subramaniam Ananthan ,  Vibha Pathak ,  Peter King

IPC: C07D487/04 ,  A61K45/06 ,  C07D519/00 ,  A61P35/00 ,  A61P25/00 ,  A61P29/00

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D519/00 ,  A61P35/00 ,  A61P25/00 ,  A61P29/00

Abstract: This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.

公开(公告)号：US20230129137A1

公开(公告)日：2023-04-27

申请号：US17968113

申请日：2022-10-18

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Jianyi Zhang ,  Yang Zhou

IPC: A61K9/51 ,  A61K31/427 ,  A61P9/10

Abstract: In one aspect, the disclosure relates to nanoparticle compositions including TT-10 or a pharmaceutically acceptable salt thereof and nanoparticles including at least one biocompatible polymer or copolymer such as poly-lactic-co-glycolic acid. Also disclosed are methods for improving at least one cardiac function or property following heart damage in a subject, the methods including at least the step of administering the nanoparticle compositions to the subject. In another aspect, the nanoparticle compositions can be administered by intraperitoneal injection and are active at a target site for a period of at least 4 weeks.

公开(公告)号：US11560413B2

公开(公告)日：2023-01-24

申请号：US16277888

申请日：2019-02-15

Applicant: UAB Research Foundation ,  Texas Tech University System

Inventor： John C. Kappes ,  Zhengrong Yang ,  Christie G. Brouillette ,  Ina L. Urbatsch

IPC: C07K14/47 ,  C07K14/705 ,  G01N33/68

Abstract: The present invention is directed to modified CFTR proteins or fragments thereof that contain single or multiple amino acid mutations to improve the structural stability of such CFTR proteins and/or fragments. Specifically, the modified CFTR proteins or fragment thereof differ from the wild-type human CFTR protein or fragment thereof by the presence of four or more mutations selected from V150D, M470V, S492P, F494N, S495P, A534P, I539T, G550E, G551D, R553Q, R555K, Q637R, S1255L, K1334G, S1359A, E1371Q, H1402S, Q1411D, and any combination thereof, such that the stability of the polypeptide is increased relative to that of the wild-type human CFTR polypeptide or fragment thereof.

公开(公告)号：US11524010B2

公开(公告)日：2022-12-13

申请号：US17374100

申请日：2021-07-13

Applicant: SOUTHERN RESEARCH INSTITUTE ,  THE UAB RESEARCH FOUNDATION

Inventor： Corinne E. Augelli-Szafran ,  Omar Moukha-Chafiq ,  Mark J. Suto ,  Anath Shalev ,  Lance Thielen ,  Junqin Chen ,  Gu Jing

IPC: A61K31/517 ,  A61K31/5377 ,  A61P1/16 ,  A61P3/06 ,  A61P3/10

Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20220387001A1

公开(公告)日：2022-12-08

申请号：US17774462

申请日：2020-11-13

Applicant: THE UAB RESEARCH FOUNDATION ,  THE CHILDREN'S OF ALABAMA

Inventor： David ASKENAZI ,  Lynn DILL ,  Martin Dawson HOLLAND ,  Shelby LEVERETT ,  Elizabeth DECHANT

IPC: A61B10/00 ,  A61F5/455

Abstract: A urine collection device is provided. The urine collection device includes a basin configured to fit a perineal region of a female human subject and to receive urine; a lip attached to the basin and having a contact surface for attachment to the perineal region; a ridge extending into the basin and disposed along an inferior portion of the lip to prevent leakage of urine from the basin; and a drain opening in the basin for draining the urine. The urine collection device advantageously prevents leakage and allows for easy access for urine analysis and measurement of urine output. Methods and systems for collecting and quantifying urine are also provided.

公开(公告)号：US20220144911A1

公开(公告)日：2022-05-12

申请号：US17427475

申请日：2020-01-30

Applicant: UAB Research Foundation

Inventor： Mark R. Walter ,  Ashlesha Deshpande

IPC: C07K14/54 ,  A61K47/65

Abstract: This invention relates to fusion proteins, nucleic acid molecules, DNA constructs, and pharmaceutical compositions comprising the same, and methods of their use in IL10 antagonism.

公开(公告)号：US20220119511A1

公开(公告)日：2022-04-21

申请号：US17503113

申请日：2021-10-15

Applicant: The UAB Research Foundation

Inventor： Gangjian QIN ,  Aijun QIAO

IPC: C07K16/18 ,  A61K31/713

Abstract: Disclosed are novel treatments for diseases and conditions caused by, directly or indirectly, high blood glucose levels increased gluconeogenesis. Such disease and conditions include, but are not limited to, type II diabetes, obesity, and cardiovascular conditions. Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis and global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. The treatments described herein may include inhibition of the activity of Sam68.

公开(公告)号：US11292817B2

公开(公告)日：2022-04-05

申请号：US16997032

申请日：2020-08-19

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Michael Niederweis ,  Mikhail Pavlenok

IPC: C12Q1/00 ,  C07K14/35 ,  C12Q1/6869 ,  G01N27/447 ,  G01N33/487

Abstract: Provided herein are mutant single-chain Mycobacterium smegmatis porin (Msp) and uses thereof.

公开(公告)号：US11213507B2

公开(公告)日：2022-01-04

申请号：US16081494

申请日：2017-04-17

Applicant: University of South Florida ,  UAB Research Foundation

Inventor： Bill J. Baker ,  Lindsey N. Shaw ,  James Bruce McClintock ,  Charles D. Amsler ,  Jacqueline Lee Fries ,  Witowski G. Christopher ,  Renee M. Fleeman

IPC: A61K31/365 ,  A61P31/04 ,  A61K9/00

Abstract: Provided is a darwinolide compound having a previously undescribed carbon skeleton and the crystalline form thereof. Also provided are processes of isolating darwinolide, compositions comprising darwinolide, and methods of treating infection, such as a methicillin-resistant Staphylococcus aureus biofilm infection.